PTC Therapeutics (PTCT) Stock Price, News & Analysis

Company Overview

PTC Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs include small-molecule treatments, gene therapies and other approaches designed to address conditions with limited or no available treatment options.

The company’s commercial portfolio has included Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy authorized in the European Union for aromatic L-amino acid decarboxylase deficiency. PTC also developed Translarna (ataluren) for certain patients with nonsense mutation Duchenne muscular dystrophy; the product has been available in some international markets, although its regulatory status has changed over time.

PTC Therapeutics was founded in 1998 and is headquartered in Warren, New Jersey. The company serves patients and healthcare providers in the United States and international markets through its own commercial operations and partnerships. Its development pipeline has historically focused on rare neurological, metabolic and genetic disorders.

Key Stats

• Today's Range: $59.64 to $65.34
• 50-Day Range: $59.24 to $73.47
• 52-Week Range: $58.80 to $90.87
• Volume: 2.36 million shs
• Average Volume: 1.01 million shs
• Market Capitalization: $5.01 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $95.64
• Consensus Rating: Moderate Buy

PTC Therapeutics Stock Analysis - MarketRank™

PTC Therapeutics scored higher than 81% of companies evaluated by MarketBeat, and ranked 133rd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

PTC Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 1 strong buy rating, 10 buy ratings, 3 hold ratings, and 2 sell ratings.

Upside Potential

PTC Therapeutics has a consensus price target of $95.64, representing about 59.5% upside from its current price of $59.97.

Amount of Analyst Coverage

PTC Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 59.66%

Earnings Growth

Earnings for PTC Therapeutics are expected to grow by 59.66% in the coming year, from $1.19 to $1.90 per share.

Price to Earnings Growth Ratio

PTC Therapeutics has a PEG Ratio of 1.95. PEG Ratios above 1 indicate that a company could be overvalued.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

10.51% of the float of PTC Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

PTC Therapeutics has a short interest ratio ("days to cover") of 7.59.

Change versus previous month

Short interest in PTC Therapeutics has recently decreased by 9.44%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PTC Therapeutics does not currently pay a dividend.

Dividend Growth

PTC Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.40

News Sentiment

PTC Therapeutics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 18 news articles for PTC Therapeutics this week, compared to 6 articles on an average week.

MarketBeat Follows

3 people have added PTC Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, PTC Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,322,261.00 in company stock.

Percentage Held by Insiders

5.30% of the stock of PTC Therapeutics is held by insiders.

Percentage Held by Institutions

PTC Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 10/29/2026
• Today: 10/30/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PTCT
• CIK: 1070081
• Web: www.ptcbio.com
• Phone: (908) 222-7000
• Fax: 908-222-7231
• Employees: 991
• Year Founded: 1998

Price Target and Rating

• Average Price Target for PTC Therapeutics: $95.64
• High Price Target: $137.00
• Low Price Target: $50.00
• Potential Upside/Downside: +59.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 16 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 50.39
• P/E Growth: 1.95
• Net Income: $682.64 million
• Net Margins: -9.17%
• Pretax Margin: -6.65%
• Return on Equity: N/A
• Return on Assets: -0.10%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.39
• Quick Ratio: 3.28

Sales & Book Value

• Annual Sales: $1.73 billion
• Price / Sales: 2.89
• Cash Flow: $8.17 per share
• Price / Cash Flow: 7.34
• Book Value: ($2.56) per share
• Price / Book: -23.43

Miscellaneous

• Outstanding Shares: 83,460,000
• Free Float: 79,038,000
• Market Cap: $5.01 billion
• Optionable: Optionable
• Beta: 0.49